Stockreport

Vertex (VRTX) Moves Kidney Disease Drug to Phase 3 Development [Yahoo! Finance]

CRISPR Therapeutics AG - Common Shares  (CRSP) 
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm Check Earnings Report
US:NASDAQ Investor Relations: nasdaq.com/symbol/crsp/real-time
PDF This phase III portion will evaluate a 45 mg oral dose of Vertex's drug, on top of standard of care, in AMKD patients, compared with placebo. Management also expanded t [Read more]